You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
斯迪克(300806.SZ):擬與蘇州宇昂 、森松製藥共設羣創智慧新材料公司 註冊資本3億元

格隆匯6月29日丨斯迪克(300806.SZ)公佈,公司擬與蘇州宇昂產業投資有限公司(簡稱“蘇州宇昂”)、上海森松製藥設備工程有限公司(簡稱“森松製藥”)共同出資設立江蘇羣創智慧新材料有限公司(簡稱“目標公司”),公司於2022年6月28日與蘇州宇昂、森松製藥就該次對外投資相關事宜簽署了《投資協議》。

目標公司註冊資本擬定為人民幣3億元,其中蘇州宇昂認繳出資1.8億元,認繳出資比例為60%;森松製藥認繳出資6000萬元,認繳出資比例為20%;斯迪克認繳出資6000萬元,認繳出資比例為20%,均以貨幣資金出資。其經營範圍包括聚酰亞胺薄膜、多層共擠高阻隔複合膜、多基共擠複合材料的產品研發、生產與銷售等。

公司與蘇州宇昂、森松製藥的合作,是各方優勢互補、資源共享的結果。中國的生命科學支持產業鏈目前正走在全面國產化替代的道路上,生物反應器作為產業鏈上的一環,其發展也達到了新的高度,其中一次性生物反應袋的市場需求日益旺盛。公司在流延技術上有多年的行業積累,成熟的技術團隊,對產品理解深刻。

合作方森松國際自成立以來就專注於生物製藥領域,與醫藥行業的客户合作長達數十年,擁有成熟的生物反應技術以及配套的技術隊伍和營銷網絡,能全方位為客户提供生產原料藥、液體和固體制劑設備。結合公司的技術平台與森松國際的銷售網絡,目標公司擬引進全球最先進的共擠流延設備,充分保障產品的順利開發和市場推廣。公司也藉此將戰略佈局由消費電子、電子元器件、新能源汽車電子延伸到生物製藥領域。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account